The decisions made by agencies like the U.S
Together, the effects of stimulating insulin, reducing glucagon, and delaying gastric emptying improve glycemic control, resulting in a favorable hypoglycemia profile
Insurance coverage for GLP-1s is expanding A key development in the growth of GLP-1 usage, at least in the U.S., is in the realm of health insurance and coverage
Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors not yet licensed by the MHRA or EMA for use in the UK
Long-term storage at 20 C, protected from light
13 These findings suggest that supporting gut health with probiotics, prebiotics, and fiber may indirectly enhance GLP-1 activity and overall metabolic function